Kornimate/medical-research-clean huggingface dataset:
an observational, epidemiological study on the prevalence of human papillomavirus types in women in egypt

Conditions: Human Papillomavirus Infection

Summary: the purpose of the study is to determine the human papillomavirus (hpv) prevalence and hpv type distribution among women aged \>= 18 years, attending out-patient health services for gynaecological examination and who agree to hpv testing in egypt .


Eligibility criteria:
inclusion criteria: * women \>= 18 years of age attending a clinic for gynaecological examination. * women who agree to provide a cervical sample for human papillomavirus testing. * written informed consent obtained from the subject. exclusion criteria: * referral for abnormal cervical sample at the current visit. * abundant menstrual bleeding or vaginal discharge not allowing appropriate screening to be performed. * history of hysterectomy. * known diagnosis of immunosuppression, or patient on immunosuppressives. * pregnant women. * having received one or more doses of hpv vaccine prior to participating in the study.
real-world experience of icis plus chemotherapy for advanced escc.

Conditions: Metastatic Esophageal Squamous Cell Carcinoma

Summary: this study is a multi-center, non-interventional study. clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (escc) patients.

this study is a multi-center, non-interventional study. patients' background, treatment pattern, treatment outcome, efficacy will be collected in metastatic esophageal squamous cell carcinoma (escc) patients who were treated with icis as 1st line treatment at approximately 26 institutions. the patients should have received at least 1 cycle of anti-pd-1 immunotherapy with or without radiotherapy. based on these data, overall survival (os), progression free survival (pfs) from start of 1st line treatment and the role and efficacy of radiotherapy for these patients will be assessed.

Eligibility criteria:
inclusion criteria: age \> 18, had an eastern cooperative oncology group performance status score of 0-3; patients had unresectable or recurrent disease that precluded esophagectomy or definitive chemoradiation, or distant metastatic disease; patients had received no previous systemic therapy (patients who had progressed ≥6 months after \[neo\]adjuvant therapy or definitive chemoradiation were eligible); patients accepted at least one cycle of anti-pd-1 immunotherapy as 1st line treatment, combined chemotherapy was allowed. patients who provided informed consent by appropriate methods. in dead case, optout will be applicable. exclusion criteria: patients who are prior exposure to immune-mediated therapy.
automated control of end-tidal volatile anesthetic concentration

Conditions: Delayed Recovery From Anesthesia

Summary: the new mirus system as well as the established anaconda system uses a reflector to conserve volatile anaesthetics (va). both systems act with commercially available icu ventilators. in contrast to anaconda the mirus includes an automated control of end-tidal va concentrations. in this study the investigators compared feasibility, costs and recovery times after anaesthesia with isoflurane (iso), sevoflurane (sevo) or desflurane (des) in ventilated and spontaneously breathing patients.

the study was approved by the appropriate institutional review board. after written informed consent 63 asa i-iii patients undergoing elective hip or knee replacement surgery under general anesthesia were included. patients were randomly organized into 3 groups (20-22 each). anesthesia was induced with intravenous anaesthetics. after tracheal intubation mirus automatically adjusted the end-tidal va concentration to 1.0 mac. patients were ventilated with the puritan bennett 840 icu ventilator. after 1 h of anaesthesia with 1.0 mac the ventilator mode was switched from simv v+ (totally controlled ventilation, "passive patient", with a tidal volume of 8 ml/ibw) to proportional assist ventilation (pav) with 50% support ("active patient"). at the end of surgery the mirus system was stopped (mac set to 0.0) and recovery times were measured.

Eligibility criteria:
inclusion criteria: * signing of the informed consent document (patient or relatives). * patient age 18 years or older. * asa i-iii exclusion criteria: * asa iv patients * epidural or spinal analgesia * allergy or known hypersensitivity to any of the study drugs * patients with known or suspected genetic susceptibility to malignant hyperthermia * previous participation in this trial * participation in another clinical trial within 4 weeks prior to selection. * pregnant women

Keywords: et control inhalational sedation conserve volatile anesthetics
autologous bone marrow-derived stem cell transplantation in patients with premature ovarian failure (pof)

Conditions: Premature Ovarian Failure

Summary: this is an open label, single arm, single center investigation to assess the safety and efficacy of purified adult autologous bone marrow derived specific populations of stem cells and mesenchymal stem cells injected into the ovaries (intraovarian injection), through a 12 week follow-up period. the investigators' chosen model of study is based on increasing the efficiency of the approach by choosing an autologous model which preserves the genetic composition of an individual that is vital in infertility conditions. additionally the approach involves transplanting a combination of specific purified stem cell types which all aid in ovarian function recovery.

premature ovarian failure (pof) is characterized as hypergonadotropic ovarian failure mostly prevalent before age 40. it is astonishingly frequent and affects around 1% of women below the age of 40. the clinical findings include amenorrhea and abnormally high levels of luteinizing (lh) and follicle stimulating hormone (fsh). the etiology of pof is unidentified in the majority of cases. it can occur due to a combination of genetics, immunological diseases, and environmental factors. pof is characterized by lack of secondary follicles, arrested folliculogenesis, decreased estrogen levels, and female infertility. currently, no available therapeutic intervention has been verified effective in retrieving fertility in patients with pof. several trials at ovarian stimulation are typically ineffective. consequently, the diagnosis of pof can cause great physical and emotional distress among patients. hence, there is serious need to develop innovative treatment plans for pof. the latest research shows that reduced ovarian reserve is caused by aging of the niche rather than a defect in germ cell lines. current scientific evidence suggests that bone marrow-derived mesenchymal stem cells (bmscs) could repair injured tissues and holds great promise in treating many diseases including male and female infertility. the uniqueness of this study is demonstrated in the transplantation of purified specific populations of autologous bone marrow derived stem cells and mesenchymal stem cells (bmscs) into patients with pof without in vitro expansion or culture, with minimal manipulation. stem cells are withdrawn and transplanted back into the patient on the same day of the procedure, thus presenting the highest safety and efficacy parameters.

Eligibility criteria:
inclusion criteria: * female * age : 20-39 * fsh\>20 exclusion criteria: * thyroid dysfunction * immunological conditions * past history of malignancy/cemotherapy/radiotherapy * infectious diseases: hiv+, hepatitis b+, c+ * abnormal karyotype * previous surgical management of ovarian pathology * severe endometriosis
attention control treatment for post traumatic stress disorder ׂ(ptsd)

Conditions: PTSD

Summary: the purpose of this study is to explore the efficacy of attention control training for post traumatic stress disorder (ptsd). act was found to be effective in decreasing attention bias variability and ptsd symptoms in combat veterans (badura-brack, et al., 2015). it is now important to continue the examination of act's efficacy in additional populations of patients with ptsd. such extension of treatment to other traumatic experiences raises the question of whether the threatening content of the training material could be personalized for each patient.

the aim of this study is to explore the efficacy of attention control training for post traumatic stress disorder (ptsd). act was found to be effective in decreasing attention bias variability and ptsd symptoms in combat veterans (badura-brack, et al., 2015). it is now important to continue the examination of act's efficacy in additional populations of patients with ptsd. such extension of treatment to other traumatic experiences raises the question of whether the threatening content of the training material could be personalized for each patient. for this purpose, we will recruit participants that are diagnosed with ptsd and will be randomly assigned to one of three conditions: personalized act, non-personalized act, or control training we expect that personalized act will produce greater reduction in ptsd symptoms relative to a non-personalized act, and that both these conditions will be more effective in symptoms reduction than a control condition not designed to affect attention or expose patients to threat stimuli. we also expect the act conditions to reduce attention bias variability relative to the control condition.

Eligibility criteria:
inclusion criteria: meeting a current diagnosis of post-traumatic stress disorder (ptsd) according to dsm-v (american psychiatric association, 2013); exclusion criteria: 1. a diagnosis of psychotic or bipolar disorders. 2. a diagnosis of a neurological disorder (i.e., epilepsy, brain injury). 3. suicidal ideation. 4. drugs or alcohol abuse. 5. non-fluent hebrew. 6. a pharmacological treatment that is not stabilized in the past 3 months (a stable treatment will not be a reason for exclusion from the study). 7. pregnancy. -

Keywords: ptsd attention training cognitive bias modification
ivermectin for severe covid-19 management

Conditions: COVID-19

Summary: in this multicenter study; it was aimed to investigate the effectiveness and safety of ivermectin use in the treatment of patients with severe covid-19 pneumonia that have no mutations which alter ivermectin metabolism and cause side effects.

patients with severe covid-19 pneumonia were included in the study. two groups, the study group and the control group, took part in the study. ivermectin 200 mcg/kg/day for five days (9 mg between 36-50 kg, 12 mg between 51-65 kg, 15 mg between 66-79 kg and 200 microgram/kg in \> 80 kg) in the form of a solution prepared for enteral use added to the reference treatment protocol -hydroxychloroquine (2x400mg loading dose followed by 2x200mg, po, 5 days) + favipiravir (2x1600mg loading dose followed by 2x600mg maintenance dose, po, total 5 days) + azithromycin (first day 500mg followed by 4 days 250mg/day, po, total 5 days)- of patients included in the study group. patients in the control group were given only reference treatment with 3 other drugs without ivermectin. the mutations in 29 pairs of primers in mdr1/abcab1 gene by sequencing analysis using sanger method, and the haplotypes and mutations of the cyp3a4 gene that cause the function losing were investigated among the patients who meet criteria and who were included in the study group according to randomization. mutation screening was done when the first dose of the research drug ivermectin was given, ivermectin treatment was not continued in patients with mutations detected as a result of genetic examination and these patients were excluded from the study. patients were followed for 5 additional days after treatment. at the end of the treatment and follow-up period (at the end of 10th day), clinical response and changes in oxygenation and laboratory parameters were evaluated.

Eligibility criteria:
inclusion criteria: * patients who were hospitalised with a pre-diagnosis of "severe covid-19 pneumonia" and thereafter diagnosis of covid-19 was also confirmed microbiologically with pcr positivity in respiratory tract samples were included into the study. they were randomized to the study and control group, respectively. patients with at least one of the criteria below were accepted as patients with severe covid-19 pneumonia; 1. presence of tachypnea ≥ 30/minute, spo2 level \< 90% in room air, pao2/fio2 \<300 in oxygen receiving patient 2. presence of specific radiological finding for covid-19 in lung tomography (bilateral lobular, peripherally located, diffuse patchy ground glass opacities) 3. mechanical ventilation requirement 4. acute organ dysfunction findings; patients with sofa (sepsis-related organ failure assessment) score \>2 exclusion criteria: * patients with the following characteristics were excluded from the study. 1. pediatric patients; \<18 years of old 2. patients with chronic liver or kidney disease 3. pregnant women 4. patients with known ivermectin allergy

Keywords: ivermectin sars-cov-2 treatment
autobiographical memory flexibility training (memflex) for posttraumatic stress disorder

Conditions: Post Traumatic Stress Disorder

Summary: the experience of trauma not only impacts the way an individual thinks and feels, but can also produce changes in the way someone remembers their personal past. it is not only memories of the trauma that are affected- avoidance of trauma memories can also lead to memories of other events becoming vague, and in particular, memories of positive experiences can seem out of reach. this memory difficulty promotes posttraumatic stress disorder (ptsd). this study will explore an intervention that aims to improve memory difficulties, which should then flow on to improve ptsd. the study will be completed with individuals who have experienced a single incident trauma. twenty five participants will complete memflex straight away, and 25 will go on a waiting list. once this first group has finished memflex, the researchers will compare the two groups to see if the programme produced a larger reduction in ptsd symptoms. memflex is workbook-based, and as such, if it is successful it may offer an easy, cheap, and accessible way to offer psychological treatment to ptsd sufferers around the world.


Eligibility criteria:
inclusion criteria: * diagnosis of posttraumatic stress disorder (as indexed by the farsi version of the structured clinical interview for dsm disorders \[scid\]) * aged over 18 years exclusion criteria: * lack of oral and/or written fluency in farsi * traumatic brain injury or cognitive impairment, indexed via self-report * current experience of psychosis, indexed by scid
the acute and accumulative effects of snack foods on exercise recovery

Conditions: Muscle Strength

Summary: the purpose of the research is two-fold. one goal is to determine if post-exercise almond or cereal bar consumption can promote muscle gain as well as increasing muscular strength throughout an eight-week weight training program. the other goal is to assess the short-term effects of almonds or cereal bar on recovery that may explain the overall long-term adaptations.


Eligibility criteria:
inclusion criteria: * bmis of 18.5-30 kg/m2 * participate in no more than 3 hours of structured exercise per week exclusion criteria: * weight training more than 30 min/week, * smoking, * use of medications known to impact inflammation, * musculoskeletal limitations, * use of supplements within 1 month of participation that are known to impact body composition, antioxidant or inflammatory status, * regular consumption of more than 2 servings of nuts per week, * unwillingness to refrain from recovery treatments during the study such as hydrotherapy, massage, stretching, compression garments, anti-inflammatory medications and topical applications.
a retrospective study of the effects of ocular acupuncture on ocular motor nerve palsy

Conditions: Oculomotor Nerve Palsy; Trochlear Nerve Palsy; Abducens Nerve Paralysis

Summary: this retrospective observational study is designed to assess the response to treatment with ocular acupuncture and its relative factors, in terms of diplopia status, ocular motility differences, and clinical features, in ocular motor nerve palsy patients. during this study, a retrospective data collection will be carried out using the information contained in the medical record of aimed patients, provided that the treatment with ocular acupuncture.


Eligibility criteria:
inclusion criteria: * age over 18 years old * patient who received at lease 1 times of ocular acupuncture treatment * patient who received full set of ophthalmology \& neurology assessment pre- and post-treatment. exclusion criteria: * patient who combined with extraocular muscles diseases, eg.thyroid eye disease * patient who underwent periocular surgery * patient who combined with congenital ocular motor nerve palsy, eg. brown syndrome. * patient who had untreated condition which may lead to ocular motor nerve palsy such as intracranial aneurysm and brain tumor.

Keywords: diplopia; ocular motor nerve palsy; acupuncture
pain management associated with the insertion of jaydess® in nulliparous women

Conditions: IUD Insertion Complication

Summary: a multicenter prospective interventional comparative study that investigate pain management during jaydess insertion in nulliparous women that will be tested by the analgesic affects of oral tramadol or 'verbal anesthesia' on the patients.

most intrauterine contraception (iuc) insertions do not require pain management. however, small proportions of nulliparous women experience substantial pain that needs to be proactively managed no prophylactic pharmacological intervention has been adequately evaluated to support routine use for pain reduction during or after iuc insertion. women's anxiety about the procedure may contribute to higher levels of perceived pain, which highlights the importance of counselling, and creating a trustworthy, unhurried and professional atmosphere in which the experience of the provider also has a major role; a situation frequently referred to as 'verbal anaesthesia'. it has been proven in the past that the use of oral tramadol can reduce the pain in the insertion. in the study investigators will compare the analgesic affects of oral tramadol and verbal anesthesia on pain relief during jaydess insertion in nulliparous women.

Eligibility criteria:
inclusion criteria: * nulliparous women aged 18-48 years, interested in a long acting, reversible contraception method. each read and signed the informed consent. exclusion criteria: women suffering from: * acute or recurrent pelvic inflammatory disease. * acute cervicitis or acute vaginitis. * current cervical intraepithelial lesion. * current any genital malignancy. * progesterone hypersensitivity. * progesterone-sensitive tumours (e.g. breast tumours). * abnormal vaginal bleeding. * congenital or acquired uterine anomaly. * distorted uterine cavity e.g. fibroid or polyp. * impaired liver functions, or liver tumour. * known hypersensitivity to the active substance or to any of the excipients of jaydess. * contraindications to tramadol according to approved product information: * in hypersensitivity to tramadol or any of the excipients. * in patients who are receiving monoamine oxidase inhibitors or within 2 weeks (14 days) of their withdrawal. * in patients with epilepsy not adequately controlled by treatment. * vaginismus.
a safety study utilizing yondelis and doxorubicin in patients with a type of cancer called soft tissue sarcoma

Conditions: Soft Tissue Sarcoma; Sarcoma; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms

Summary: the purpose of the study is to determine the dose of the combination of trabectedin (yondelis) and doxorubicin for which neutropenia (low white blood cell counts) could be managed with filgrastim (a granulocyte-colony stimulation factor that is used to help control neutropenia) in patients with a type of cancer called soft tissue sarcoma.

this is a multicenter, open-label (identity of the assigned study treatments will be known to patients and study staff) study to determine the dose of the combination of trabectedin (yondelis) and doxorubicin for which the neutropenia (low white blood cell counts) is manageable with the use of filgrastim (an agent used to manage neutropenia) and associated with clinically acceptable number of side effects severe enough to continuation of treatment in patients with recurrent or persistent soft tissue sarcoma (sts, a malignant tumor that attacks the body's infrastructure of fat, muscles, nerves, joints, blood vessels, or deep skin tissues). patients will be enrolled in the study after all study-specific entry criteria are met and informed consent is obtained. patients will be required to attend regular clinic visits to receive study medication and have their status monitored. a detailed explanation can be provided by the study physician (investigator) conducting this study. doxorubicin (50 to 75 mg/m2) will be given as a 10-15 minute intravenous (i.v.) infusion on day 1 via a central venous catheter which is a tube placed into a large vein. trabectedin (0.9 to 1.3 mg/m2) will be given as a 3 hour i.v. infusion, immediately following the administration of doxorubicin. dexamethasone 20 mg will be given within 1 hour before the start of each doxorubicin i.v. infusion and filgrastim will be administered according to manufacturer's instructions.

Eligibility criteria:
inclusion criteria: * have a diagnosis of soft tissue sarcoma, recurrent or persistent * signed informed consent obtained for all patients before performing any study-related procedures exclusion criteria: * patients treated with more than 1 prior chemotherapy regimen (including adjuvant (or other additional) therapy) * previous exposure to anthracyclines (a class of drugs used in cancer chemotherapy, example is doxorubicin) or trabectedin * less than 4 weeks since radiation therapy * known metastases (spread) of cancer to the central nervous system * other ongoing serious illness present at the time of enrollment as determined by the investigator

Keywords: doxorubicin adriamycin trabectedin yondelis ecteinascidin 743 filgrastim, antineoplastic antineoplastic agents pharmacologic actions alkylating agents
metabolomic profiling of in patients with type2 diabetes

Conditions: Diagnoses Disease; Diabetes Mellitus, Type 2

Summary: to exam the metabolomic profiling of csf and plasma in diabetes and establish the human csf metabolome database of type 2 dm.

human cerebral spinal fluid (csf) is known to be a rich source of small molecule biomarkers for central neurological and neurodegenerative diseases. however, the metaboloic bases of csf in diabetes patient have not been studied. in this plan, the investigators will use analytical platforms, including nuclear magnetic resonance (nmr), liquid chromatography-mass spectrometry (lc-ms), to perform quantitative metabolomics on human csf and blood samples and further establish the human csf metabolome database of dm. this work will can supply important csf metabolic profit information and help to facilitate a wide range of metabolomic studies on central nervous system diseases and their associations disease.

Eligibility criteria:
inclusion criteria: diabetes group 1. .20-75 years of age 2. .type 2 diabetes patient by clinical diagnosis 3. .american association of anesthesiologists (asa)≦iii control group (non-diabetic group): 1. .20-75 years of age 2. .no history of dm and other systemic illness 3. .american association of anesthesiologists (asa)≦ ii exclusion criteria: 1. patient refuses to sign informed consent 2. patients with coagulopathy, systemic infective disease and severe liver and renal function impairment. 3. patients with spine or brain tumor and severe cns disease. 4. the presence of severe and/or uncontrolled and/or unstable medical disease within 12 months prior to study other than dm which could compromise participation in the study (e.g. acute pancreatitis, stroke, liver cirrhosis, congestive heart failure, and systemic immune disorder etc. 5. concurrent participation or planning to participate in another interventional clinical trial (concurrent participation in an observational trial allowed) -